Medicine and Dentistry
Prostate Cancer
100%
Prostate Specific Membrane Antigen
73%
Positron Emission Tomography-Computed Tomography
48%
Polyethylene Terephthalate
45%
Gallium 68
43%
Positron Emission Tomography
36%
Lutetium 177
20%
Biochemical Recurrence
18%
Fluorine-18
18%
Radiation Therapy
18%
Neoplasm
18%
Prostatectomy
17%
Castration Resistant Prostate Cancer
16%
Prostate Specific Antigen
15%
Lymph Node
13%
Radioligand
13%
Magnetic Resonance Imaging
11%
Diagnosis
10%
Metastatic Carcinoma
10%
Positron Emission Tomography - Magnetic Resonance Imaging
10%
Radioactive Tracer
9%
Radiosurgery
9%
Recurrent Disease
9%
Lymph Node Metastasis
8%
Retroperitoneal Lymph Node Dissection
8%
Choline
8%
Pelvis
8%
Diseases
8%
Retrospective Study
8%
Fluorodeoxyglucose F 18
8%
Carbon 11
7%
Magnetic Resonance Imaging
7%
Dosimetry
7%
Computer Assisted Tomography
6%
Oncology
5%
Histopathology
5%
Biopsy Technique
5%
Clinical Trial
5%
Overall Survival
5%
Molecular Imaging
5%
Keyphrases
Prostate-specific Antigen
87%
Prostate Cancer
52%
Positron Emission Tomography-computed Tomography (PET-CT)
40%
Lutetium-177 (177Lu)
26%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
22%
PET-MRI
22%
Positron Emission Tomography
20%
Recurrent Prostate Cancer
18%
Radical Prostatectomy
14%
PSMA PET-CT
14%
Radioligand Therapy
14%
Prostate Cancer Patients
14%
Biochemical Recurrence
12%
PET Imaging
11%
Prostate-specific Membrane Antigen Positron Emission Tomography
11%
PSMA PET
10%
Gallium-68
9%
Tumor
9%
Radioguided Surgery
9%
Patients with Prostate Cancer
9%
Primary Prostate Cancer
8%
PSMA-617
8%
Lymph Node Metastasis
8%
High-grade Prostate Cancer
7%
Lymph Node
6%
Dosimetry
6%
Salvage Radiotherapy
6%
68Ga-PSMA-11
6%
Multicenter Retrospective Study
6%
Multiparametric MRI (mpMRI)
6%
Whole-body
5%
Hybrid Radio
5%
Overall Survival
5%
Theranostics
5%
Magnetic Resonance Imaging
5%
SUVmax
5%
Radiation Therapy
5%
Conventional Imaging
5%
Metastasis
5%
Diagnostic Performance
5%